DRCR Retina Network

From #NEIfunded DRCR network (@DrcrNet): Factors for meeting criteria to switch from bevacizumab to aflibercept in people with center-involved diabetic macular edema & moderate vision loss. @JaebCenter @JoslinDiabetes @ClevelandClinic @AAOjournal: bit.ly/46oMI74

Our Senior Biostatistician Wesley Beaulieu and Executive Director Adam Glassman provide more insight into how the Archway trial tested new treatments for macular degeneration in this invited commentary from last summer;pubmed.ncbi.nlm.nih.gov/35708698/

DRCR's Protocol AC primary results from NEJM nejm.org/doi/full/10.10… as a top 10 Ophtho Article of the Last Year blog.doximity.com/articles/the-t…

DEFINING “STRONG” VERSUS “WEAK” RESPONSE TO ANTIVASCULAR... : RETINA journals.lww.com/retinajournal/…

At 4 years, treatment of nonproliferative diabetic retinopathy with aflibercept vs sham treatment resulted in statistically significant anatomic improvement, but no improvement in visual acuity. ja.ma/3JKVJOB

Aflibercept to Prevent Vision Complications of Diabetic Retinopathy, Review of Managing Menopausal Symptoms, and more. Listen to a summary of the February 7 issue of JAMA by Editor in Chief @KBibbinsDomingo. ja.ma/3RFdqko

Visual acuity measurements from ETDRS protocol testing tend to be better than Snellen measurements recorded in clinical practice. Differences were greater when clinical measurements were lower and when they were taken without refraction. @DrcrNet ow.ly/cq1N50M712Q

@DrcrNet Protocol W 4 year results: For mod-sev NPDR, q4 mon intravitreal antiVEGF offered no visual acuity benefit vs treating only if complications developed @rmaturi ja.ma/3JKVJOB

Dr. Jhaveri discusses DRCR Retina Network Protocol AC theretinachannel.com/e64-drcr-proto…

In recent years, the DRCR #Retina Network has expanded its studies to include other #retinaldiseases beyond DR. Here is a look at the @DRCRNet’s recently published and ongoing trials. retinatoday.com/articles/2022-…

#Podcast: JAMA Ophthalmology Web Editor Neil Bressler, MD, and authors @DrcrNet and @AdamGlassman1 discuss "Association of Predominantly Peripheral Lesions on Ultrawide Field Imaging and the Risk of Diabetic Retinopathy Worsening Over Time." ja.ma/3A2hmU5

Interview with Adam R. Glassman, MS, and Jennifer K. Sun, MD, MPH on Peripheral Lesions on UWF Imaging and Risk of Diabetic Retinopathy Worsening. ja.ma/3wfIEp0

Diabetic retinopathy can cause vision loss and blindness in people with #diabetes. Watch this video to explore what life might look like with vision loss caused by diabetic retinopathy. For the audio-described version, visit youtu.be/QG2Kr3i9gbc #EyeHealthEducation

#NEIfunded clinical trial led by @DrcrNet found that in diabetic macular edema, starting with a cheaper drug (Avastin) and switching to a more expensive drug (Eylea) as needed leads to good vision outcomes. @NIDDKgov Read the NEI News report: bit.ly/3O7GtK0

New editorial by David C. Musch, Ph.D, M.P.H., and Emily Chew, M.D.: "Evidence for Step Therapy of Diabetic Macular Edema" #ASRS2022 nej.md/3PqogbU

Some insurance companies mandate a form of step therapy, which involves a trial of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and a more expensive drug. #ASRS2022 nej.md/3P9FA4X

#NEIfunded researchers from @DrcrNet found that surgery and drug therapy work equally well for diabetic eye disease. Read more: nei.nih.gov/about/news-and… #NEInews

While intravitreal injection of aflibercept may be a safe alternative for initial management of vitreous hemorrhage from proliferative diabetic retinopathy (PDR), vitrectomy with panretinal photocoagulation remains the standard of care for PDR. ja.ma/34gXqxv

On Capitol Hill today—A Congressional luncheon spotlighting @NatEyeInstitute’s Diabetic Retinopathy Clinical Research Network @DrcrNet and their ongoing research on #DiabeticEyeDisease. Thank you, Dr. Daniel Martin @ClevelandClinic & Dr. Jennifer Sun @JoslinDiabetes!